Vital Therapies closes $28.1m round:
This article was originally published in Clinica
Manufacturer of the ELAD (extracorporeal liver assist device) artificial liver Vital Therapies (VTI) has completed a $28.1m series C financing round. The round, which was led by Versant Ventures, will support the San Diego, California-based company's development of what it claims to be the world's only human cell-based artificial liver. The firm is preparing to file for marketing approval of ELAD in China, and advance its US clinical programme of the product. The financing included the participation of new investors Delphi Ventures, HBM BioMed China and DFJ DragonFund China, and existing shareholders MedVenture Associates, Valley Ventures, Toucan Capital and Heights Capital. The financing sees Versant Ventures' Dr Ross Jaffe join the VTI board of directors.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.